Clinical Trials · NCT00933361
Individual Dose-escalated Bi-daily Subcutaneously (sc) Ghrelin in Cancer Cachexia: a Phase I/II Study
- Phase
- Phase 1/Phase 2
- Recruitment status
- Completed
- Sponsor
- Cantonal Hospital of St. Gallen
- Enrollment
- 21
- Start date
- Jun 2009
- Locations
- 1 site, Switzerland
- Primary endpoint
- To assess the dose of ghrelin in tumour patients with ACS causing optimal stimulation of nutritional intake - minimal dose for maximal nutritional intake (MD-MANI) - or the maximally tolerable dose (MTD), which one occurs first